Follow Us:
Flurbiprofen

Ansaid

Flurbiprofen

Flurbiprofen is a medication used to relieve pain, inflammation, and swelling associated with conditions such as arthritis, musculoskeletal disorders, and postoperative pain. It belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin production responsible for pain and inflammation.

Dosage Form:
Dosage Strength:
CAS No.: 5104-49-4
Status:
Manufacturer:
Group: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Sub Group: Non-selective COX inhibitors
Class: Propionic Acid Derivatives

Uses of Flurbiprofen

Flurbiprofen was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

  • Rheumatoid arthritis: Relief of joint pain, swelling, and inflammation.
  • Osteoarthritis: Management of pain and stiffness associated with degenerative joint disease.
  • Musculoskeletal disorders: Treatment of back pain, sprains, strains, muscle injuries, and joint inflammation.
  • Menstrual pain: Relief of primary dysmenorrhoea and associated abdominal cramps.
  • Headaches and migraines: Management of certain headaches and acute migraine attacks.
  • Dental pain: Relief of pain and inflammation associated with toothache and dental procedures.
  • Postoperative pain: Short-term management of pain following selected surgical procedures.
  • Acute gout: Treatment of pain and inflammation during acute gout attacks, when clinically appropriate.
  • Fever: Reduction of elevated body temperature with suitable medicines and doses.

Contraindication of Flurbiprofen

Flurbiprofen was historically subject to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Known hypersensitivity to the medicine, aspirin, or other NSAIDs.
  • Previous serious allergic reactions, including NSAID-induced asthma or urticaria.
  • Active peptic ulcer disease or gastrointestinal bleeding.
  • Severe renal impairment or severe hepatic impairment.
  • Severe heart failure or certain serious cardiovascular conditions.
  • Active pathological bleeding or significant bleeding disorders.
  • Perioperative pain management associated with coronary artery bypass graft (CABG) surgery.
  • Late pregnancy, particularly from 30 weeks onward.

Precautions for Flurbiprofen

Flurbiprofen was majorly subjected to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Gastrointestinal effects: These medicines may cause stomach irritation, peptic ulcers, gastrointestinal bleeding, and, rarely, gastrointestinal perforation.
  • Cardiovascular risk: Use cautiously in patients with hypertension, heart disease, previous stroke, or fluid retention, as some medicines may increase cardiovascular risks.
  • Kidney impairment: Propionic acid derivatives may reduce renal blood flow and cause kidney injury, particularly in patients with existing kidney disease or dehydration.
  • Liver function: Liver enzyme abnormalities may occur during treatment. Monitoring may be necessary during prolonged use.
  • Asthma and allergies: Patients with aspirin-sensitive asthma or previous NSAID-related allergic reactions should avoid these medicines unless specifically advised by a healthcare professional.
  • Pregnancy: Avoid routine use from 20 weeks of pregnancy unless specifically advised by a healthcare professional. Use from 30 weeks onward is generally avoided.
  • Elderly patients: Older adults may have an increased risk of gastrointestinal bleeding, kidney complications, and cardiovascular adverse effects.
  • Treatment duration: Use the lowest effective dose for the shortest appropriate period.

Drug Interactions for Flurbiprofen

Potential drug interactions were historically documented when Flurbiprofen was prescribed alongside certain medications. These included:

  • Anticoagulants: Warfarin and direct oral anticoagulants may increase the risk of gastrointestinal and other bleeding.
  • Antiplatelet medicines: Aspirin and clopidogrel may increase bleeding risk when combined with propionic acid derivatives.
  • Corticosteroids: Prednisolone and other corticosteroids may increase the risk of gastrointestinal ulcers and bleeding.
  • ACE inhibitors and ARBs: Concurrent use may reduce blood-pressure control and increase the risk of kidney injury.
  • Diuretics: These NSAIDs may reduce diuretic effectiveness and increase the risk of fluid retention and renal impairment.
  • Lithium: Ibuprofen, naproxen, and other NSAIDs may increase lithium concentrations and the risk of toxicity.
  • Methotrexate: NSAIDs may reduce methotrexate clearance and increase the risk of toxicity, particularly at higher methotrexate doses.
  • Other NSAIDs: Combining multiple NSAIDs increases gastrointestinal, renal, and cardiovascular adverse-effect risks.
  • Antihypertensive medicines: These medicines may reduce the effectiveness of certain blood-pressure-lowering treatments

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Flurbiprofen.

The Flurbiprofen is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Flurbiprofen.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Flurbiprofen, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Flurbiprofen Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Flurbiprofen

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Flurbiprofen Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Flurbiprofen, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Flurbiprofen

The export of Flurbiprofen from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Flurbiprofen Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Flurbiprofen specifications, certificates of analysis, and other supporting documents required for Flurbiprofen export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Flurbiprofen export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Flurbiprofen regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Flurbiprofen documentation, labelling, Flurbiprofen manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Flurbiprofen Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Flurbiprofen, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.